2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-130190
    Butopamine 66734-12-1 98%
    Butopamine is the active R/R stereoisomer butapamine of ractopamine hydrochloride. Butopamine exerts its physiological effects by stimulating β1-adrenergic receptor (β1AR) and β2-adrenergic receptor (β2AR) expressed in skeletal muscle and adipose tissue.
    Butopamine
  • HY-130287
    (±)16-HDHA 90780-51-1 98%
    (±)16-HDHA is an autoxidation product of docosahexaenoic acid (DHA) in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. (±)16-HDHA is a potential marker of oxidative stress in brain and retina where DHA is an abundant polyunsaturated fatty acid.
    (±)16-HDHA
  • HY-130301
    Gallensre 142974-51-4 98%
    Gallensre (S 0960) is an apical sodium-dependent bile acid transporter inhibitor (IC50 = 5.8 μmol/L). Gallensre inhibits bile salt reabsorption in a rat model. Gallensre can be used to study metabolic diseases such as bile acid cycling.
    Gallensre
  • HY-130314
    PPHP 87864-20-8 98%
    PPHP is a substrate for the measurement of peroxidase enzymes. PPHP has been used to quantitate the peroxidase activity of COX-1 and COX-2.
    PPHP
  • HY-130319
    9(S)-HEPE 141545-44-0 98%
    9(S)-HEPE, a hydroxy fatty acid, is a metabolite of Eicosapentaenoic acid.
    9(S)-HEPE
  • HY-130439
    EUK-124 186299-35-4 98%
    EUK 8 and EUK 134 are synthetic catalytic scavengers of reactive oxygen species with superoxide dismutase (SOD) and catalase mimetic activity.1 EUK 124 is a structural analog of EUK 8 and EUK 134 with significantly reduced activity. EUK 124 and EUK 8 inhibit superoxide-mediated reduction of an electron acceptor (i.e., SOD mimetic activity), with IC50 values of 5 μM and 0.7 μM, respectively.
    EUK-124
  • HY-130573
    DMAPP 358-72-5 98%
    DMAPP (Dimethylallyl pyrophosphate) is an isoprenoid precursor. DMAPP, as an isomer of isopentenyl pyrophosphate (IPP), exists in virtually all life forms.
    DMAPP
  • HY-130658
    D-NMMA acetate 137694-75-8
    D-NMMA acetate is an inactive isomer of L-NMMA (HY-18732A). L-NMMA is a nitric oxide synthase inhibitor.
    D-NMMA acetate
  • HY-131103
    Phenylethanolamine A 1346746-81-3 98%
    Phenylethanolamine A acts as a β-adrenergic agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.
    Phenylethanolamine A
  • HY-131206
    DS37571084 2460353-87-9 98%
    DS37571084 is an orally active and potent antagonist of the parathyroid hormone type 1 receptor (PTHR1), with an IC50 value of 0.17 μM. DS37571084 can be used for the study of hyperparathyroidism.
    DS37571084
  • HY-131507
    Emepronium bromide 3614-30-0 98%
    Emepronium bromide is an antispasmodic agent for the bladder and a muscarinic receptor ligand, with an IC50 of 236 nM. Emepronium bromide is applicable to research related to bladder diseases.
    Emepronium bromide
  • HY-131528
    Tenilsetam 86696-86-8 99.79%
    Tenilsetam (CAS 997) is an antidementia compound. Tenilsetam is an advanced glycation end product (AGE) inhibitor. Tenilsetam inhibits early retinopathy in experimental diabetes rats.
    Tenilsetam
  • HY-131542
    APPA 100750-39-8 98%
    APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research.
    APPA
  • HY-131578
    Rinderine N-oxide 137821-16-0 98%
    Rinderine N-oxide is a pyrrolizidine alkaloid that can be found in R. graeca.
    Rinderine N-oxide
  • HY-131626
    1a,1b-Dihomo prostaglandin E2 26198-80-1 98%
    1a,1b-Dihomo Prostaglandin E2 (PGE2) is a rare polyunsaturated fatty acid first identified in extracts of sheep vesicular gland microsomes, known to contain COX, incubated with adrenic acid. 1a,1b-Dihomo PGE2 has also been identified in conditioned media of RAW 264.7 macrophages stimulated with endotoxin and arachidonic acid. This product is thought to be produced by elongation of AA to adrenic acid, which is then metabolized sequentially by COX and PGE synthase.
    1a,1b-Dihomo prostaglandin E2
  • HY-131736
    3'-O-Bn-GTP 1610778-75-0 98%
    3'-O-Bn-GTP (3'-O-Benzyl-5'-O-guanosine triphosphate) (CAP-164) is an analog of GTP. 3'-O-Bn-GTP has a higher stability against esterases.
    3'-O-Bn-GTP
  • HY-131760
    2'-NH2-ATP 61468-88-0 98%
    2'-NH2-ATP (2'-Amino-2'-deoxyadenosine-5'-triphosphate), an adenosine derivative, is a weak competitive inhibitor of ATP, with a Ki of 2.3 mM. 2'-NH2-ATP can be used in nucleic acid labeling.
    2'-NH2-ATP
  • HY-131962
    PKD-IN-1 956121-30-5 98%
    PKD-IN-1 (compound 32), an aminoethylamino-aryl (AEAA) compound, acts as PKD-1 inhibitor. PKD-IN-1 can be used for protein kinase D (PKD)-mediated diseases research.
    PKD-IN-1
  • HY-131995
    O-Arachidonoyl glycidol 439146-24-4 98%
    O-Arachidonoyl glycidol (compound 1) is a 2-arachidonoylglycerol (2-AG) analog. O-Arachidonoyl glycidol inhibits cytosolic 2-oleoylglycerol (2-OG) hydrolysis with an IC50 value of 4.5 µM. O-Arachidonoyl glycidol blocks 2-OG hydrolysis in membrane fractions and anandamide hydrolysis with IC50s of 19, 12 µM, respectively.
    O-Arachidonoyl glycidol
  • HY-132178
    Cytochrome P450 9035-51-2
    Cytochrome P450 is a family of monooxygenase enzymes that catalyzes the conversion of fatty acids to terminal alkenes using hydrogen peroxide as a cosubstrate. Cytochrome P450 as membrane-bound hemoproteins, plays important roles in the detoxification of drugs, cellular metabolism, and homeostasis.
    Cytochrome P450
Cat. No. Product Name / Synonyms Application Reactivity